Back to Search

A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma

  • Protocol Number: 202202142
  • Principal Investigator: Thaker, Premal
  • Cancer Types: Gynecologic

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions